Ignite Creation Date:
2025-12-24 @ 7:57 PM
Ignite Modification Date:
2025-12-25 @ 5:31 PM
Study NCT ID:
NCT05776004
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-08
First Post:
2023-02-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
Sponsor:
Eagle Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-07-22
Start Date Type:
ACTUAL
Primary Completion Date:
2026-02-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-09-07
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-14
First Submit QC Date:
None
Study First Post Date:
2023-03-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-07
Last Update Post Date:
2025-10-08
Last Update Post Date Type:
ESTIMATED